BVT Knock-Out GNMSF/ DE000VA80VU7 /
2024-05-28 1:43:03 PM | Chg.+0.180 | Bid3:45:27 PM | Ask3:45:27 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
12.540EUR | +1.46% | 12.330 Bid Size: 8,000 |
12.350 Ask Size: 8,000 |
Genmab A/S | 1,030.86 DKK | 2078-12-31 | Call |
GlobeNewswire
05-21
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO A...
GlobeNewswire
05-17
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
GlobeNewswire
05-14
Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization...
GlobeNewswire
04-30
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...
GlobeNewswire
04-22
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
GlobeNewswire
04-07
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persis...
GlobeNewswire
04-03
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
GlobeNewswire
03-20
BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
GlobeNewswire
03-20
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
GlobeNewswire
03-11
BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidat...
GlobeNewswire
03-06
BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update ...
GlobeNewswire
03-04
Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of ...
GlobeNewswire
02-08
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Exp...
GlobeNewswire
02-08
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Exp...
GlobeNewswire
01-31
BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjuga...
GlobeNewswire
01-22
BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/...